-
that could help develop new individualized therapies for cancer!
Time of Update: 2021-03-06
of integrin and tarin, which may help understand the biological phenomena mediated by cytocytosin subjects and hopefully help develop new ways to treat cancer. in the cell membrane, the integratant forms a connection between the cytostebrae
-
Cell: Scientists hope to use stem cell therapy to successfully correct skull and brain function
Time of Update: 2021-03-06
" structure in young mice. researchers say that by supplementing the stem cells, they may be able to regenerate flexible "stitching" structures in affected animal bodies. To test the idea, the researchers added Gli1 plus cells from healthy
-
Roche has signed a contract with Dyno Therapeutics, a gene therapy vector
Time of Update: 2021-03-06
signed a partnership agreement with Dyno Therapeutics to develop adenovirus (AAV) vectors for gene therapy for central nervous system (CNS) disease and liver targeted therapy. Under the terms of the agreement
-
Alnylam's third RNAi therapy lumasiran is about to be approved by the European Union
Time of Update: 2021-03-06
, the largest interventional study in the PH1 group. In the study, patients were randomly assigned a 2:1 ratio to be treated with lumasiran or a placebo. lumasiran is given at a dose of 3 mg/kg, treated once a month for 3 months, and then maintained
-
CDE proposed breakthrough therapy identified: Amjin KRAS inhibitor AMG 510 treatment NSCLC
Time of Update: 2021-03-06
occurs in about 25% of cancer cases, mainly in lung, pancreatic and colorectal cancers, and is associated with very poor disease prognostois. , KRASG12C mutation is one of the most common KRAS mutations, specifically kras 12-bit glycine mutation
-
Roche Tecentriq's joint Avastin therapy was approved in Europe
Time of Update: 2021-03-06
In addition, China's State Administration of Pharmaceutical Products has approved the combination therapy in October 2020 to treat non-removable HCC patients who have not previously received systematic treatment.
-
Gene Therapy: Methods and Application
Time of Update: 2021-03-06
, to treat or prevent a disease1 – 3 ). The process involves a group of technologies that enable the intentional transfer of specific exogenous genetic information into cells and the application of these technologies for pharmaceutical
-
GlaxoSmithKline's dual-drug HIV therapy is to be included in the priority review
Time of Update: 2021-03-05
China's State Drug Administration Drug Review Center (CDE) recently announced that the two-drug HIV therapy submitted by GlaxoSmithKline (GSK) - Dotiravirpivirin tablets of the new drug market application to be included in the priority review
-
The FDA stopped Voyager gene therapy to treat Huntington's disease
Time of Update: 2021-03-05
Later on Tuesday, Cambridge, Massachusetts-based Voyager announced that the FDA had issued a clinical stay on its application for a new drug (IND) for the company's gene therapy VY-HTT01 for huntington's disease.
-
Lilly's application for a new drug to develop RNAi gene therapy is authorized
Time of Update: 2021-03-05
November 16, RNA Interference (RNAi) gene therapy drug developer Dicerna Pharmaceuticals, Inc., announced that the FDA has now authorized a new drug application (IND) code-named LY3561774, the first clinical phase drug candidate for Dierna in partnership with Lilly.
-
Sanofi Pompe bay disease therapy is eligible for FDA priority review
Time of Update: 2021-03-05
A key double-blind drug-controlled Phase 3 clinical trial assessed the safety and efficacy of avalglucosidase alfa compared to α-glucosidease (standard treatment) in patients with late-haired Pompeidase.
-
FDA approves the first long-acting HIV injection therapy only once a month
Time of Update: 2021-03-05
The FDA today announced the approval of Cabenuva (Cabotwe and Lipivirin, injection preparations) developed by ViiV Healthcare as a complete solution for treating adults with HIV-1 infection who develop viral inhibitions after receiving antiretroviral therapy.
-
Bladder cancer is heavy! EU approves Merck/Pfizer immunotherapy Bavencio for first-line maintenance therapy: will change clinical practice!
Time of Update: 2021-03-04
that in all two major groups of randomly grouped patients and tumor PD-L1-positive patients, bavencio-BSC first-line maintenance therapy significantly extended total survival (OS) and significantly increased one-year survival rates compared to Best Support
-
CD19 CAR-T Cell Therapy! The first three total Yescarta was approved in Japan: treatment of recurrence / incurable large B cell lymphoma!
Time of Update: 2021-03-04
January 26, 2021 // -- Daiichi Sankyo recently announced that Japan's Ministry of Health, Labour (MHLW) has approved Yescarta (axicabtagene ciloleucel), a CD19-guided chiline antigen (CAR) T-cell therapy for the treatment of certain relapsed/refractic large B-cell lymphoma (LBCL) adults.
-
Science: A complete map of viral mutations reveals that new coronavirus mutations can evade antibody therapy
Time of Update: 2021-03-04
January 26, 2021 /--- In a new study, researchers from the Fred Hutchinson Cancer Research Center and the University of Washington and other research institutions have developed a new way to map viral mutations that "escape" major clinical
-
Cell Stem Cell Interpretation! Scientists have developed a new DNA therapy that promises to remove
Time of Update: 2021-03-04
used ION251 to remove myeloma stem cells without damaging healthy blood cells. 'These preclinical results are so striking that half of the microscope images we compared bone marrow samples between treated mice and untreated mice have been blank
-
Research and development of new dual base editing tools to aid gene therapy
Time of Update: 2021-03-04
expression levels than cells that produced C-to-T base editing alone. Zhang Xiaohui, co-lead author of the paper and a doctoral student at the School of Life Sciences at East China University, explains that this means that the new dual-base editing system
-
The study found gender specificity in Alzheimer's therapy
Time of Update: 2021-03-04
many drug candidates may have different effects between different genders, we need to be extra cautious in our future clinical trial designs," said Abdelrahman, a research institute.
-
Blood: Sickle-type blood disease therapy is also effective for COVID19
Time of Update: 2021-03-03
January 29, 2021 // -- In a recent study, scientists found a way to reduce the risk of stroke in sickle cell patients, providing new ideas for potential treatment of inflammation and blood clotting symptoms caused by COVID-19, among others.
-
The first gist precision therapy ayvakit Phase 3 clinical failure
Time of Update: 2021-03-03
In 2017, a Phase 1 clinical study showed that the drug had a 100% disease control rate, a 100% tumor reduction rate, and a 12-month PFS rate of 78% in patients with PDGFR alpha exon 18 D842V mutant GIST.
